近期中外幽门螺杆菌根除治疗处理共识报告对比解读

Reconciliation of recent western and eastern consensus on treatment of Helicobacter pylori eradication

幽门螺杆菌(Helicobacter pylori,H.pylori)是主要的胃癌致病因子,也是消化系统内外多种疾病的重要致病因素,为了规范H.pylori的治疗以降低胃癌发病率,国内外相关共识也在不断更新。2022年,中国和欧洲均发布了最新的H.pylori处理共识报告,即《2022中国幽门螺杆菌感染治疗指南》和《幽门螺杆菌感染的管理:马斯特里赫特Ⅵ/佛罗伦萨共识报告》,本文将从H.pylori根除治疗的抗生素管理、根除方案、根除流程、根除疗程、加强抑酸、其他辅助用药六个方面回顾上述指南并进行对比解读,为临床规范化根除H.pylori治疗提供参考依据。

Helicobacter pylori(H.pylori)is a major pathogenic factor for gastric cancer and an important pathogenic factor for gastrointestinal disease and affects other human systems.In order to regulate the treatment of H.pylori and reduce the incidence of gastric cancer,western and eastern consensus is constantly updated.In 2022,both China and Europe released the latest consensus reports on H.pylori management,namely″2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment″and″Management of Helicobacter pylori infection:the MaastrichtⅥ/Florence consensus report″.In this paper,the above guidelines would be reviewed and compared from six aspects:antibiotic management,eradication program,eradication process,eradication course,enhancement of acid inhibition and other adjuvant drugs,so as to provide reference for standardized clinical eradication of H.pylori therapy.